<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7E833A22-66FB-41DB-BB4E-283D08AF9A6E"><gtr:id>7E833A22-66FB-41DB-BB4E-283D08AF9A6E</gtr:id><gtr:name>Janssen Research &amp; Development</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/58704C20-A72D-49C0-BE60-977383C307F5"><gtr:id>58704C20-A72D-49C0-BE60-977383C307F5</gtr:id><gtr:name>Araclon Biotech</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/42E115D6-74A7-41AB-8729-C3F169DB4ECC"><gtr:id>42E115D6-74A7-41AB-8729-C3F169DB4ECC</gtr:id><gtr:name>Ixico</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D7900CE2-A312-427D-AB82-2F88341AE2B5"><gtr:id>D7900CE2-A312-427D-AB82-2F88341AE2B5</gtr:id><gtr:name>SomaLogic</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Psychiatry</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7E833A22-66FB-41DB-BB4E-283D08AF9A6E"><gtr:id>7E833A22-66FB-41DB-BB4E-283D08AF9A6E</gtr:id><gtr:name>Janssen Research &amp; Development</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/58704C20-A72D-49C0-BE60-977383C307F5"><gtr:id>58704C20-A72D-49C0-BE60-977383C307F5</gtr:id><gtr:name>Araclon Biotech</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/42E115D6-74A7-41AB-8729-C3F169DB4ECC"><gtr:id>42E115D6-74A7-41AB-8729-C3F169DB4ECC</gtr:id><gtr:name>Ixico</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D7900CE2-A312-427D-AB82-2F88341AE2B5"><gtr:id>D7900CE2-A312-427D-AB82-2F88341AE2B5</gtr:id><gtr:name>SomaLogic</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/BC9C56EA-4DD4-465B-A008-0A598A608E40"><gtr:id>BC9C56EA-4DD4-465B-A008-0A598A608E40</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Matthews</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A64B614B-387F-4A87-8F08-18C3C2916676"><gtr:id>A64B614B-387F-4A87-8F08-18C3C2916676</gtr:id><gtr:firstName>Julie</gtr:firstName><gtr:surname>Williams</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/09717709-C72F-4D1D-A890-7310F654D410"><gtr:id>09717709-C72F-4D1D-A890-7310F654D410</gtr:id><gtr:firstName>Carol</gtr:firstName><gtr:surname>Brayne</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8BE1E05D-66EC-4BC1-984E-A885E5880F7D"><gtr:id>8BE1E05D-66EC-4BC1-984E-A885E5880F7D</gtr:id><gtr:firstName>Marcus</gtr:firstName><gtr:surname>Richards</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7A46BA4B-96A3-426F-A462-0A99B3A8D601"><gtr:id>7A46BA4B-96A3-426F-A462-0A99B3A8D601</gtr:id><gtr:firstName>Cathie</gtr:firstName><gtr:surname>Sudlow</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E31A811E-4DC9-442C-8BCB-7E05986CFD98"><gtr:id>E31A811E-4DC9-442C-8BCB-7E05986CFD98</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Gallacher</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8087A3C3-09A8-4495-8205-03AF95BFFB0E"><gtr:id>8087A3C3-09A8-4495-8205-03AF95BFFB0E</gtr:id><gtr:firstName>Jean</gtr:firstName><gtr:surname>Manson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7BDAB136-9238-446B-9EE2-3CC6A8606FC5"><gtr:id>7BDAB136-9238-446B-9EE2-3CC6A8606FC5</gtr:id><gtr:firstName>Craig</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Ritchie</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9B8C6561-A7B1-4005-94C5-F62552C54593"><gtr:id>9B8C6561-A7B1-4005-94C5-F62552C54593</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Lovestone</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/788CCC41-829E-4273-863B-33B991E33E67"><gtr:id>788CCC41-829E-4273-863B-33B991E33E67</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Starr</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7D6560DD-5C24-443C-9C64-BC770B160A0A"><gtr:id>7D6560DD-5C24-443C-9C64-BC770B160A0A</gtr:id><gtr:firstName>Ronan</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Lyons</gtr:surname><gtr:orcidId>0000-0001-5225-000X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3F80F013-4083-41DC-A241-BB6959CDACAB"><gtr:id>3F80F013-4083-41DC-A241-BB6959CDACAB</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:otherNames>J.</gtr:otherNames><gtr:surname>Deary</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/73771842-1F5F-417D-B3E9-1C95161A8FA9"><gtr:id>73771842-1F5F-417D-B3E9-1C95161A8FA9</gtr:id><gtr:firstName>Nick</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Fox</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5B264FD6-EE14-4E6D-B52A-BC7460F89146"><gtr:id>5B264FD6-EE14-4E6D-B52A-BC7460F89146</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:otherNames>Neil</gtr:otherNames><gtr:surname>Rossor</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/AA8AFD7A-1956-462F-941F-96D2F16657AC"><gtr:id>AA8AFD7A-1956-462F-941F-96D2F16657AC</gtr:id><gtr:firstName>Jonathan Mark</gtr:firstName><gtr:surname>Schott</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FL023784%2F2"><gtr:id>0313B1D6-7DDD-4108-97C5-58170CF3B819</gtr:id><gtr:title>UK Dementias Platform</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/L023784/2</gtr:grantReference><gtr:abstractText>The UK Dementias Platform (UKDP) is a radically new approach to dementias research, bringing together data from around 2,000,000 study participants from 22 cohorts to try and discover the causes of dementia and to find out ways of slowing it down. The platform has been funded to the level of &amp;pound;4.5M and invited to apply for a further &amp;pound;7.5M. 

To achieve our goals of discovering the causes of dementia and finding out ways to slow it down, we will analyse data collected over many decades from throughout the UK to identify targets for drugs studies. 

We will also enrich strategically selected cohorts to provide resources for dementias research in general. This will involve finding out how the early dementia processes begin, how our genes affect our risk of dementia and where our body goes wrong in maintaining and repairing itself. 

There are many practical challenges involved in doing this work including knowing how to assess dementia in large studies where having everyone examined by a doctor would be prohibitively expensive. Another challenge is how to measure cognitive decline in the population as when people begin to decline they are frequently less motivated to do cognitive tests.

There are also important ethical issues surrounding this work and we have specific projects looking at ethical legal and social issues surrounding taking part in detailed measurement studies as well as in considering brain donation.

To help make an impact as soon as possible, we will work closely with industry partners who are best placed to turn basic scientific knowledge into effective therapies.

Even if we cannot cure dementia in the short term, it would count as a success if we found ways of slowing it down so that nobody need lose their dignity as they grew older.</gtr:abstractText><gtr:technicalSummary>The UK Dementias Platform (UKDP) is a radically new approach to dementias research, providing a highly efficient and cost-effective translation pipeline from basic discovery through to early phase trials (Fig 1). By combining the analytic and statistical power of &amp;gt;20 clinical and population cohorts representing 2M participants and creating a large readiness cohort, UKDP will create an optimal environment for basic discovery activities relevant to the clinical progression and human impact of dementia. Although UKDP is intended as a strategic and sustainable resource generating increasing scientific benefit over time, it will also deliver short and medium term benefits through the analysis of existing data, the enrichment of strategically selected cohorts, developing new ways of working with industry, and generating interest and further funding for dementias research generally.

A single portal informatics hub (funded in stage 1) will be used for integrating data from participating cohorts and triangulating evidence between cohorts. The stage 2 proposal focuses on providing strategic resources for EM by enriching strategically selected cohorts, addressing key methodological issues and pump-priming a programme of EM studies.

Further development of the platform is anticipated as the opportunities it provides are more widely understood. For example, predicated on the ability of the platform's ability to provide accurately risk stratification, MRC and NIHR have recently funded a deep and frequent Phenotyping (DFP) feasibility study with a view to providing a further &amp;pound;5M for the full study. The DFP project may be considered a stage 3 development of UKDP and is an example of how UKDP can be used to leverage further resource for dementias research.</gtr:technicalSummary><gtr:potentialImpactText>The platform will use several vehicles to deliver impact. 

These were described in stage 1. 

In summary:

For the academic community, in addition to the proposals mad in stage 1, we will develop a network of partnerships and operate a system of working groups to actively consult the UK academic community and world experts on the direction, technologies and collaborations of the platform. Our aim is to 1) base the science of the platform on the best information available, 2) create momentum in dementias research by being inclusive of, and synergistic with, other initiatives.

For industry, partnership discussions are already underway with exchanges of ides, interests and needs between academic and industry stakeholders. Industry have identified their need for access to conversion (early MVI to dementia cohorts and for experimental medicine studies to conform to regulatory requirements.

We remain committed to raising the profile of contemporary debate about dementia and its treatment. We wish to encourage a culture of commitment to solving this problem. By increasing awareness at all levels of society we intend to leverage resources for the platform and for dementia research in general, to increase awareness of the need for earlier interventions and better targeted treatment in general by health service providers and the public alike.

Engagement with the general public and with patients and carers is a very important part of our mission. This serves not only to communicate our research findings and their relevance but also to address such issues as stigma in society and the research culture in the NHS in relation to dementia and older people. In addition to using the platform web-site to communicate to the general public, we will also liaise with charities and advocate groups such as Age UK and the Alzheimer's Society to promote our work and findings and to engage them in shaping the work programme.

In addition we will have a dedicated free-phone number available 6 days a week and a communications officer at 50% FTE over 5 years whose responsibility is to develop and implement a communications and public engagement strategy.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-06-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>13248413</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>SomaLogic</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>DPUK industry partnership</gtr:description><gtr:id>E7636B9B-A19D-45CE-B03C-6509F505BE94</gtr:id><gtr:impact>Please refer to the following link:

http://brain.oxfordjournals.org/content/138/12/3673</gtr:impact><gtr:partnerContribution>Expertise and technologies</gtr:partnerContribution><gtr:piContribution>The Dementias Platform UK provides a research infrastructure for developing new treatments for dementia</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Araclon Biotech</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>DPUK industry partnership</gtr:description><gtr:id>7D7DACAF-2545-42F5-ACA6-D031604C92D8</gtr:id><gtr:impact>Please refer to the following link:

http://brain.oxfordjournals.org/content/138/12/3673</gtr:impact><gtr:partnerContribution>Expertise and technologies</gtr:partnerContribution><gtr:piContribution>The Dementias Platform UK provides a research infrastructure for developing new treatments for dementia</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>AZ Medimmune</gtr:department><gtr:description>DPUK industry partnership</gtr:description><gtr:id>763C608F-006B-4F9D-BC01-FFB7E028A92E</gtr:id><gtr:impact>Please refer to the following link:

http://brain.oxfordjournals.org/content/138/12/3673</gtr:impact><gtr:partnerContribution>Expertise and technologies</gtr:partnerContribution><gtr:piContribution>The Dementias Platform UK provides a research infrastructure for developing new treatments for dementia</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Medical Research Council (MRC), MRC Cognition and Brain Sciences Unit</gtr:department><gtr:description>Insight 46</gtr:description><gtr:id>8AF8B590-B570-4CFA-9968-F7B70B27ECAC</gtr:id><gtr:impact>N/A</gtr:impact><gtr:partnerContribution>N/A</gtr:partnerContribution><gtr:piContribution>Collaborating with colleagues at the UCL MRC National Survey for Health and Development, Institute of Molecular Neuroscience, and Institute of Nuclear Medicine, Insight 46 is a major prospective two-time point (0, 12m) MRI, amyloid PET, clinical, biomarker and neuropsychological study of 500 members of the MRC National Survey for Health and Development 1946 birth cohort. This highly inter-disciplinary study involving UCL based epidemiologists, neurologists, imagers, clinical chemists, geneticists and statisticians aims to determine the earliest biomarker changes of AD, the contribution of genetic and life course influences on the development of late life cognitive impairment, and the optimal means of designing AD prevention studies. This &amp;gt;&amp;pound;5M project includes funding from ARUK, MRC Dementias Platform UK (WP4), Wolfson Foundation and Brain Research Trust, as well as industry contributions (~&amp;pound;850K, Eli Lilly). As well as coordinating the project (with Fox, Richards) I supervise a study manager, two clinical PhD students (Lane and Parker, a Wellcome Training Fellowship), and a study coordinator. The study is well underway, with &amp;gt;300 scaned; cross-sectional data will complete in October 2017; and longitudinal collection two years later.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ixico</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>DPUK industry partnership</gtr:description><gtr:id>EE368EBE-3EA8-4F44-B3F5-6C0A1630411D</gtr:id><gtr:impact>Please refer to the following link:

http://brain.oxfordjournals.org/content/138/12/3673</gtr:impact><gtr:partnerContribution>Expertise and technologies</gtr:partnerContribution><gtr:piContribution>The Dementias Platform UK provides a research infrastructure for developing new treatments for dementia</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>European Prevention of Alzheimers disease project (EPAD)</gtr:description><gtr:id>19F82483-D102-4D18-AEC0-9EC6939ED900</gtr:id><gtr:impact>Multi-disciplinary: clinicians, imagers, geneticists, statisticians, epidemiologists.</gtr:impact><gtr:partnerContribution>European colleagues are also contributing towards the trials infrastructure and recruitment tot he EPAD longitudinal cohort study</gtr:partnerContribution><gtr:piContribution>DPUK is contributing towards the trials infrastructure and recruitment tot he EPAD longitudinal cohort study</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Janssen Research &amp; Development</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>DPUK industry partnership</gtr:description><gtr:id>D9D6DEBD-CF51-4C46-AC3C-B08869AD13BE</gtr:id><gtr:impact>Please refer to the following link:

http://brain.oxfordjournals.org/content/138/12/3673</gtr:impact><gtr:partnerContribution>Expertise and technologies</gtr:partnerContribution><gtr:piContribution>The Dementias Platform UK provides a research infrastructure for developing new treatments for dementia</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Neurology and GI Centre of Excellence for Drug Discovery (CEDD) GSK</gtr:department><gtr:description>DPUK industry partnership</gtr:description><gtr:id>94F0A66B-6EA1-45AF-B825-B55A9AEE58F0</gtr:id><gtr:impact>Please refer to the following link:

http://brain.oxfordjournals.org/content/138/12/3673</gtr:impact><gtr:partnerContribution>Expertise and technologies</gtr:partnerContribution><gtr:piContribution>The Dementias Platform UK provides a research infrastructure for developing new treatments for dementia</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Alzheimer's Association International Conference (AAIC)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>79B27595-FA85-4C10-BEF3-BF501617215D</gtr:id><gtr:impact>Present research at AAIC, which is the largest international meeting dedicated to advancing dementia science. The purpose is to disseminate our research and to learn about current and novel research in dementia science.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Late night event at The Science Museum</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8C8BB5B6-0B77-4C62-AA57-97C59F97E918</gtr:id><gtr:impact>N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Many Faces of Dementia - massive open online course (MOOC)</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>50BE791F-A1D1-4719-88C3-8707AC6E75F3</gtr:id><gtr:impact>I was interviewed for an online course about the rarer forms of dementia, my interview related to the clinical features of frontotemporal dementia. I also performed the voice over and welcome to the course that appeared in the course trailer video. The course, due to start March 14th 2016 is a 'massive open online course' available at www.futurelearn.com/courses/faces-of-dementia. Over 12,000 people have registered for the course (as of 8th March 2016).</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.futurelearn.com/courses/faces-of-dementia</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Speaking re fluid biomarkers in AD. Educational Workshop. AAIC, Toronto</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FF99A464-3B3B-4E24-9228-86E00E18774C</gtr:id><gtr:impact>N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>A population perspective on dementia and its relationship with ageing and dying across time</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E17288F1-3698-45A0-8F58-52D3B6E4D938</gtr:id><gtr:impact>Invited speaker at Brocher foundation, Geneva, 14-15 April 2016. The redefinition of Alzheimer's disease and its social and ethical consequences.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Meetings with Insight46 donors via ARUK</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A20BCB6B-851F-465A-9A7B-6533018C9B2D</gtr:id><gtr:impact>Meeting with Insight46 donors via ARUK to discuss Insight46 and dementia research.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dementia: Population and Public health</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>08911A40-B84D-4BD5-ADEA-3E94BFD93350</gtr:id><gtr:impact>A talk was given for the visit of the DRI Direct on 19 Oct 2016 at University of Cambridge, IPH</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Horizon - filming 2015-16</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>347F8B67-7519-41A3-A81F-298CF813B94F</gtr:id><gtr:impact>BBC Horizon were interested in making a programme about Alzheimer's disease with a focus on novel technology - especially imaging - for early diagnosis and trials.
Several meetings were held with the produced and his team and then several days of on-site filming including following a research subject.
The film is due to be shown in Spring 2016 as a one hour long programme which is likely to reach an audience of more than a million</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>5-7 October 2016, CCNA ISAB (Vancouver)(premanifest disease &amp; cognitive footprint?)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DC06FA64-9D6B-4B0D-9490-DC0C084BD43B</gtr:id><gtr:impact>Plenary lecture at Canadian consortium on Neurodegeneration and aging</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Speaking Cambridge Dementia Course: MRI in dementia</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BC97EA94-4E8B-4B70-AF74-75E15B587A4D</gtr:id><gtr:impact>N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Speaking re young onset dementia: Royal college of Physicians, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7A522172-7665-48C1-88B2-7BEEEF09F0A1</gtr:id><gtr:impact>N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British  NeuroPsychiatric Association Annual meeting 24th February - medalist Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9DB15B5F-80AE-4F30-A28F-EB39E58F8C32</gtr:id><gtr:impact>Discussion of nosological challanges in Dementia</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://bnpa.org.uk/wp-content/uploads/2017/02/BNPA-FINAL-PROGRAMME-2017.pdf</gtr:url><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Speaking at EAN, Copenhagen, Focal dementias, Convener, lecturer</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>493A3BED-0269-45C2-AF69-9CCD80A6B00A</gtr:id><gtr:impact>N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>A moving target? Dementia in changing older populations (and a changing world)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>49017902-1BC2-4668-A0BB-A4FE7FA6A169</gtr:id><gtr:impact>A talk was given at AAIC 2016 (Alzheimer's Association International Conference) 23-28 July at Toronto Canada.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Insight 46 launch facebook offices</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E3F29671-C3E3-4BB6-B8AC-7112ED5F3599</gtr:id><gtr:impact>Talk sparked questions and included George Freeman MP - Minister for Life Sciences

A number of members of the audience asked for further information</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cheltenham Science Festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>ADFE4F13-A489-42B4-B559-F381C77F3AA5</gtr:id><gtr:impact>Talk led to a lot of questions and discussion - for almost an hour after the event

A number of people expressed interest in taking part in research</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.dementiasplatform.uk/event/cheltenham-science-festival/</gtr:url><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Q&amp;A session at Rare Dementia Support Group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>22C1FB95-9213-4F57-AD5B-B6513D30916D</gtr:id><gtr:impact>Question and Answer session from patients and carers with a diagnosis of frontotemporal dementia</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Young Onset and Rare Dementias 2014 event at House of Lords</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F7756E1F-9704-495B-9B47-C37C901F78EC</gtr:id><gtr:impact>Awareness-raising event regarding young onset and rare dementias
The event was attending by member of parliament and the House of Lords as well as charities, patient families and other organisations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>https://www.youngdementiauk.org/news/young-onset-awareness-event-house-lords</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Rare Dementia Support Group Launch 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7C727C50-3450-48D5-9968-235D8D1D7770</gtr:id><gtr:impact>Rare Dementia Support Fund created with the ambition to increase fundraising and extend the support service further, throughout the UK and beyond.
Extremely well attended</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.nationalbrainappeal.org/rare-dementia-support-launch-event/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Plenary Speaker at European Academy of Neurology on Imaging Trials and Dementia</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8D0643B2-6B38-4C2D-8F37-0229A1459106</gtr:id><gtr:impact>N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>1946 70th birthday event</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9E3586B5-CE47-4D6D-A6BA-3D54E2971C35</gtr:id><gtr:impact>The 70th Birthday Event celebrated the 70th birthday of participants in the MRC NSHD (1946 birth cohort) - we provided a display of brain imaging</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dementias Platform UK (DPUK) Scientific Symposium</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>364D000B-547C-4E18-B1C7-32FED41D7B95</gtr:id><gtr:impact>The purpose of the Symposium was for all members of DPUK to come together to discuss and learn more about the scientific activity of the Platform, specifically looking at the main themes of Cohorts, Networks and Experimental Medicine.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Speaker at Primary Progressive Aphasia: BNPA Annual Meeting, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>756187B0-4935-4742-8BC5-24B796C166D6</gtr:id><gtr:impact>N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dementia and a Research Institute - Interview in the Sun Newspaper 5Oct15</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8D655E1D-8BD1-4712-96A6-77F40BB88C90</gtr:id><gtr:impact>Publicity to promote the fact that 5p from each carrier bag bought would be donated to the Dementia Research Centre. This was the brainchild of Malcolm Walker (Iceland) with Nick Fox (DRC)</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.thesun.co.uk/sol/homepage/woman/health/health/6735025/5p-bags-could-help-combat-dementia.html</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>6-7 April 2016, DZNE (Bonn)&quot;The role of genetic cohorts in bridging clinical and basic science&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>80A8C71F-900D-4998-B5F7-E9617C5FEC4E</gtr:id><gtr:impact>Discussion of the role of Genetic cohorts to advise the German Neurodegenerative disease research network</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description> 26 April 2016, DPUK Annual Conference</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FACC0AF2-5DD3-46AB-BD83-E275A163ED2E</gtr:id><gtr:impact>DPUK Open Day</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.dementiasplatform.uk/wp-content/uploads/2016/06/Conference-Programme.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>World Innovation Summit for Health (WISH) Forum (February 2015)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F20CB198-0327-4B3E-AEDB-85B441FB0A5D</gtr:id><gtr:impact>Participated as panel member looking at issues of dementia funding and research, policy, and how best to better inform the public. A report was subsequently published based on the Summit meeting.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.nhsq.info/app/media/4053</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>November 2016, WISH Summit (Qatar)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>939AE8CE-4F7D-45E4-8B0F-8606F73DA5E2</gtr:id><gtr:impact>-</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ARUK conference 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3AB11CB8-B43D-4A29-B6CF-356626318EE7</gtr:id><gtr:impact>Lots of questions

More interest in taking part in dementia research</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Plenary speaker: Cypriot Neurological Society</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A33086D3-4D04-43CE-9E7E-BBF68ADC568F</gtr:id><gtr:impact>N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Plenary speaker: The neurology of ageing, ABN Annual Meeting, Brighton</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2A755385-ADC3-438A-9047-30EA7F1A0F15</gtr:id><gtr:impact>N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dementias Platform UK (DPUK) scientific symposium</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>ADAC7C8D-99E3-4D80-B21C-7BC79E44C503</gtr:id><gtr:impact>The purpose of this symposium was for all members of DPUK to come together to discuss and learn more about the scientific activity of the Platform, specifically look at the main themes of Cohorts, Networks and Experimental Medicine</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Population data and modelling: dementia as exemplar</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E6F669E9-8AE5-49F7-A1A9-900FDB1659F1</gtr:id><gtr:impact>A talk was given at the Cumberland initiative Festival of Evidence 5th of Oct 2016.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alzheimer's Society debate: How can we beat dementia in the next twenty years</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>527166C9-6170-4B0B-8360-635341080C2F</gtr:id><gtr:impact>Organised by the Alzheimer's Society. this involved patients, carers, supporters and the media who have had subsequent interest in research. very positive feedback from the Alzheimer's Society who were grateful for the input.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Plenary Speaker at Clinical Trials in Alzheimer's Disease (CTAD) conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>305C6C2B-B8C2-4291-A1AE-4A531A9CB424</gtr:id><gtr:impact>N/A</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Medicine and Me:  Living well with Dementia</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E66E08C4-4D3B-4EA4-BAD8-9C8124436121</gtr:id><gtr:impact>Giving a talk on types and diagnosis of dementia at this half day meeting.

The Medicine and Me series of meetings at the RSM aim to update on important conditions and gives a direct voice to patients and their carers to air their concerns on the impact of diagnosis, investigation and management. Physicians and surgeons and indeed all healthcare professionals continue to learn from and be inspired to greater efforts by our patients to improve care.
The audience at this meeting will comprise of those living with dementia, their families, carers and advocates, representing about 70% of those present; and clinicians and researchers, representing not more than 30%. Clinicians will include doctors, specialist nurses and others involved in the treatment and care of those who have this condition</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.rsm.ac.uk/events/events-listing/2015-2016/groups/public-engagement-programme/mmg01-medicine-and-me-living-well-with-dementia.aspx</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>219355</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Brain Research Trust</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Brain Research Trust (BRT)</gtr:fundingOrg><gtr:id>D01B6411-C9EF-4796-BA3A-E0D16759949F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>174791</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Bloomsbury Centre; Wellcome Trust</gtr:department><gtr:description>Wellcome Trust Clinical Training Fellowship</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>40C7C0B7-1397-49A7-A240-D10417E86172</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EU IMI-2. Amyloid imaging to prevent Alzheimer's disease (AMYPAD)</gtr:description><gtr:end>2021-09-02</gtr:end><gtr:fundingOrg>European Social Survey: European Research Infrastructure Consortium (ESS ERIC)</gtr:fundingOrg><gtr:id>7D940CBE-A4F6-41C9-8410-EBBCCE3ED818</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>249965</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Improving prevention trials in AD through imaging</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Alzheimer?s Society</gtr:fundingOrg><gtr:fundingRef>261 (AS-PG-15-025)</gtr:fundingRef><gtr:id>09106C89-BB2A-43CD-845B-659F31FB6319</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60852</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Drake Foundation: Effects of head injury the NSHD 1946 birth cohort.</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>The Drake Foundation</gtr:fundingOrg><gtr:id>68D67901-9F8D-407F-B8C6-21A41553B6B0</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1824093</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>1946 ARUK</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>B51F1C01-18C6-49BA-B4F8-F14F34AF054F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>887193</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wolfson Foundation: Ageing Cohort</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>The Wolfson Foundation</gtr:fundingOrg><gtr:id>C6FB5355-0101-401F-A55D-D50C3B9C03C2</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Alzheimer Association Educational Workshop: The basics of fluid biomarkers in AD - speaker</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>3E2AC739-45A8-47DD-9D87-04328571F478</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ABN clinical research and academic committee, London representative</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>26639AAE-1C69-4724-9804-901EEE5E4AD1</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Press conference</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>18812ECB-8930-4E06-972B-7011A6AFCA48</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Advisor WHO (World Health Organisation)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>C40AF029-C7F7-4796-9E1D-D090DC07319A</gtr:id><gtr:impact>N/A</gtr:impact><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Deputy Chair, ABN Cognitive Disorders Advisory Group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A38A033B-2C71-4698-BA12-B8CA4E4F658C</gtr:id><gtr:impact>N/A</gtr:impact><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>UCL ageing event - cultivating research connections across the university: organising committee and plenary speaker</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>37B99D56-F528-44AC-83A8-9A6F2C58A690</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Vice Chair and Chair Elect, Advisory Council US Alzheimer's Association ISTAART</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>EFC5C9BE-883A-486E-B80D-716B6B6EEE33</gtr:id><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member, Biobank access committee, Brains for Dementia Research</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>34A57165-AD18-414E-BBEC-F1AD54606459</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>UK representative - European Academy of Neurology Dementia Panel</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>EA803548-4091-44DA-ACA1-486836449A32</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B93CFEF4-5B96-4988-9279-8811599F7CE4"><gtr:id>B93CFEF4-5B96-4988-9279-8811599F7CE4</gtr:id><gtr:title>The MRC National Survey of Health and Development reaches age 70: maintaining participation at older ages in a birth cohort study.</gtr:title><gtr:parentPublicationTitle>European journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/977456e1e88d768cbc2b50dbe3f60187"><gtr:id>977456e1e88d768cbc2b50dbe3f60187</gtr:id><gtr:otherNames>Kuh D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0393-2990</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/73BDA4AB-B9AE-4DD4-A2BC-DDDE4B64482E"><gtr:id>73BDA4AB-B9AE-4DD4-A2BC-DDDE4B64482E</gtr:id><gtr:title>Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/62366058290559ad41281d7f243bbb01"><gtr:id>62366058290559ad41281d7f243bbb01</gtr:id><gtr:otherNames>Schrag A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/29DE707C-C2BB-4958-BD9D-70F2156DE6B8"><gtr:id>29DE707C-C2BB-4958-BD9D-70F2156DE6B8</gtr:id><gtr:title>The relationship between affective symptoms and hypertension-role of the labelling effect: the 1946 British birth cohort.</gtr:title><gtr:parentPublicationTitle>Open heart</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/44a2861ba8eafe7f78ab35442f583c2d"><gtr:id>44a2861ba8eafe7f78ab35442f583c2d</gtr:id><gtr:otherNames>Tikhonoff V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2053-3624</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D5841991-1932-4F25-8763-8712550AF682"><gtr:id>D5841991-1932-4F25-8763-8712550AF682</gtr:id><gtr:title>A life course approach to health literacy: the role of gender, educational attainment and lifetime cognitive capability.</gtr:title><gtr:parentPublicationTitle>Age and ageing</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7c0aafdb610e9afcb4c4402893a5e181"><gtr:id>7c0aafdb610e9afcb4c4402893a5e181</gtr:id><gtr:otherNames>Clouston SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-0729</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DE74536A-6325-49D3-8750-6E1B622A84FA"><gtr:id>DE74536A-6325-49D3-8750-6E1B622A84FA</gtr:id><gtr:title>Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6446838f83f81f804d5ac791f0f7d797"><gtr:id>6446838f83f81f804d5ac791f0f7d797</gtr:id><gtr:otherNames>Weston PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C6BBD014-55D9-48A6-836F-4BF8288B193B"><gtr:id>C6BBD014-55D9-48A6-836F-4BF8288B193B</gtr:id><gtr:title>Adolescent Self-Organization and Adult Smoking and Drinking over Fifty Years of Follow-Up: The British 1946 Birth Cohort.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/657a517be8ab6fd3040d5bdb9fedead5"><gtr:id>657a517be8ab6fd3040d5bdb9fedead5</gtr:id><gtr:otherNames>Nishida A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9022B0C6-70FE-48D8-AC18-533C0D742D5C"><gtr:id>9022B0C6-70FE-48D8-AC18-533C0D742D5C</gtr:id><gtr:title>Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?</gtr:title><gtr:parentPublicationTitle>Journal of Alzheimer's disease : JAD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6446838f83f81f804d5ac791f0f7d797"><gtr:id>6446838f83f81f804d5ac791f0f7d797</gtr:id><gtr:otherNames>Weston PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1387-2877</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BF1E9753-FAF0-43DD-B38F-ACEF394CF318"><gtr:id>BF1E9753-FAF0-43DD-B38F-ACEF394CF318</gtr:id><gtr:title>Why has therapy development for dementia failed in the last two decades?</gtr:title><gtr:parentPublicationTitle>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4887f7cb28dbdf7675cc19c781076e6d"><gtr:id>4887f7cb28dbdf7675cc19c781076e6d</gtr:id><gtr:otherNames>Gauthier S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1552-5260</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7B50AB7C-2FBD-4062-9D8A-3213BB2D3E4C"><gtr:id>7B50AB7C-2FBD-4062-9D8A-3213BB2D3E4C</gtr:id><gtr:title>Physical and cognitive capability in mid-adulthood as determinants of retirement and extended working life in a British cohort study.</gtr:title><gtr:parentPublicationTitle>Scandinavian journal of work, environment &amp; health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7cb9099b1e4362a3f816884be1ff6356"><gtr:id>7cb9099b1e4362a3f816884be1ff6356</gtr:id><gtr:otherNames>Stafford M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0355-3140</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/53755AD8-6D20-45D3-8568-2463D12274BF"><gtr:id>53755AD8-6D20-45D3-8568-2463D12274BF</gtr:id><gtr:title>Direct Parametric Reconstruction With Joint Motion Estimation/Correction for Dynamic Brain PET Data.</gtr:title><gtr:parentPublicationTitle>IEEE transactions on medical imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6dad7d5faaddcd33af62818747e2d0fb"><gtr:id>6dad7d5faaddcd33af62818747e2d0fb</gtr:id><gtr:otherNames>Jiao J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0278-0062</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/82FB10C2-28E7-4A94-89DE-FC0029BD9745"><gtr:id>82FB10C2-28E7-4A94-89DE-FC0029BD9745</gtr:id><gtr:title>Effects of vitamin B-12 supplementation on neurologic and cognitive function in older people: a randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>The American journal of clinical nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/98dec3dd03d7f6b588d510785b174431"><gtr:id>98dec3dd03d7f6b588d510785b174431</gtr:id><gtr:otherNames>Dangour AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9165</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5D8EA41A-2796-4890-860C-5A86B6E58CCD"><gtr:id>5D8EA41A-2796-4890-860C-5A86B6E58CCD</gtr:id><gtr:title>Prospective associations between adolescent mental health problems and positive mental wellbeing in early old age.</gtr:title><gtr:parentPublicationTitle>Child and adolescent psychiatry and mental health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/657a517be8ab6fd3040d5bdb9fedead5"><gtr:id>657a517be8ab6fd3040d5bdb9fedead5</gtr:id><gtr:otherNames>Nishida A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1753-2000</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/479ED011-1A3F-4232-BBF6-F8974DB94AEB"><gtr:id>479ED011-1A3F-4232-BBF6-F8974DB94AEB</gtr:id><gtr:title>Poor Balance as a Noncognitive Predictor of Incident Dementia.</gtr:title><gtr:parentPublicationTitle>Journal of the American Geriatrics Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f37516b1c2d831f39a236d48d26aa4a2"><gtr:id>f37516b1c2d831f39a236d48d26aa4a2</gtr:id><gtr:otherNames>Lee AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-8614</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D8DD3B6A-D02A-445A-A44E-62635D8D2DEF"><gtr:id>D8DD3B6A-D02A-445A-A44E-62635D8D2DEF</gtr:id><gtr:title>Verbal memory and search speed in early midlife are associated with mortality over 25 years' follow-up, independently of health status and early life factors: a British birth cohort study.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2c8c78ef79a6c5af275104b65fc05b3d"><gtr:id>2c8c78ef79a6c5af275104b65fc05b3d</gtr:id><gtr:otherNames>Davis D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D53CE2CD-1927-4E19-8176-A8CE14497403"><gtr:id>D53CE2CD-1927-4E19-8176-A8CE14497403</gtr:id><gtr:title>Intensity and Types of Physical Exercise in Relation to Dementia Risk Reduction in Community-Living Older Adults.</gtr:title><gtr:parentPublicationTitle>Journal of the American Medical Directors Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f37516b1c2d831f39a236d48d26aa4a2"><gtr:id>f37516b1c2d831f39a236d48d26aa4a2</gtr:id><gtr:otherNames>Lee AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1525-8610</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2FCD388C-2B64-47B1-89DC-B31379D7EA5E"><gtr:id>2FCD388C-2B64-47B1-89DC-B31379D7EA5E</gtr:id><gtr:title>White matter hyperintensities are associated with disproportionate progressive hippocampal atrophy.</gtr:title><gtr:parentPublicationTitle>Hippocampus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1c61eff9b24ccc7c0cf635fef61cb3b9"><gtr:id>1c61eff9b24ccc7c0cf635fef61cb3b9</gtr:id><gtr:otherNames>Fiford CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1050-9631</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/35F99736-2299-45E0-AD85-F5F77AFC0D35"><gtr:id>35F99736-2299-45E0-AD85-F5F77AFC0D35</gtr:id><gtr:title>Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-? Concentration.</gtr:title><gtr:parentPublicationTitle>Journal of Alzheimer's disease : JAD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a896c05ff079b09bbd8b7d45f25746b3"><gtr:id>a896c05ff079b09bbd8b7d45f25746b3</gtr:id><gtr:otherNames>Toombs J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1387-2877</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A1000578-4DC1-47A5-8FC8-29FE84FB634B"><gtr:id>A1000578-4DC1-47A5-8FC8-29FE84FB634B</gtr:id><gtr:title>Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b2f8dfe154301fda0ca7dc5fa167fe8"><gtr:id>9b2f8dfe154301fda0ca7dc5fa167fe8</gtr:id><gtr:otherNames>Ryan NS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/67E085FF-010F-4EF5-96F6-24B15E5197F7"><gtr:id>67E085FF-010F-4EF5-96F6-24B15E5197F7</gtr:id><gtr:title>Parent-child relationships and offspring's positive mental wellbeing from adolescence to early older age.</gtr:title><gtr:parentPublicationTitle>The journal of positive psychology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7cb9099b1e4362a3f816884be1ff6356"><gtr:id>7cb9099b1e4362a3f816884be1ff6356</gtr:id><gtr:otherNames>Stafford M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1743-9760</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DD2C3650-E1B5-45F6-B26A-23398F95556B"><gtr:id>DD2C3650-E1B5-45F6-B26A-23398F95556B</gtr:id><gtr:title>Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress.</gtr:title><gtr:parentPublicationTitle>Molecular diagnosis &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b3e20fda70740751de85d30c038b636"><gtr:id>1b3e20fda70740751de85d30c038b636</gtr:id><gtr:otherNames>Keshavan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1177-1062</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/82502D6F-FA89-4EA5-B6C3-E2EB00C8E536"><gtr:id>82502D6F-FA89-4EA5-B6C3-E2EB00C8E536</gtr:id><gtr:title>Multimodal Image Analysis in Alzheimer's Disease via Statistical Modelling of Non-local Intensity Correlations.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d410b9903f6823797eb686df00539115"><gtr:id>d410b9903f6823797eb686df00539115</gtr:id><gtr:otherNames>Lorenzi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ACA8FDB9-8437-4F77-B285-CC5F433055D7"><gtr:id>ACA8FDB9-8437-4F77-B285-CC5F433055D7</gtr:id><gtr:title>A high-fat, high-glycaemic index, low-fibre dietary pattern is prospectively associated with type 2 diabetes in a British birth cohort.</gtr:title><gtr:parentPublicationTitle>The British journal of nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/75f8840c01a06c04b84697bb83079db1"><gtr:id>75f8840c01a06c04b84697bb83079db1</gtr:id><gtr:otherNames>Pastorino S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-1145</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F1240838-81E0-4291-A84B-042B05806D46"><gtr:id>F1240838-81E0-4291-A84B-042B05806D46</gtr:id><gtr:title>BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c738a7cf905389dba329a747a71140a1"><gtr:id>c738a7cf905389dba329a747a71140a1</gtr:id><gtr:otherNames>Lim YY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D698C523-BB57-4567-A087-330D4840F79B"><gtr:id>D698C523-BB57-4567-A087-330D4840F79B</gtr:id><gtr:title>Psychometric Validation of the Parental Bonding Instrument in a U.K. Population-Based Sample: Role of Gender and Association With Mental Health in Mid-Late Life.</gtr:title><gtr:parentPublicationTitle>Assessment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ef76cefd3c4ac54d12d853b654adaaa0"><gtr:id>ef76cefd3c4ac54d12d853b654adaaa0</gtr:id><gtr:otherNames>Xu MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-1911</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/L023784/2</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>93C4699B-9E5C-4982-9CCC-EFD5B9712D6E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.6  Resources and infrastructure (aetiology)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>